In the non-CAD group, 134 (74.86%) were taking metformin, 121 (67.60%) were on sulphonyl urea, 58 (32.40%) were on DPP-4 inhibitors, 34 (18.99%) on SGLT-2 inhibitors, seven (3.91%) were on alpha-glucosidases inhibitors, and two patients were on pioglitazone. This evidence concerns the gene SLC5A2 and coronary artery disorder.